Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — BIO-Europe Spring 2026
29 slides from Tonix Pharmaceuticals's conference presentation, March 2026
Slide 1: BIO-Europe Spring Presentation March 2026
BIO-Europe Spring Presentation March 2026 NASDAQ: TNXP © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “
Slide 3: Tonix Pharmaceuticals – Transforming Medicine for the Future
Tonix Pharmaceuticals – Transforming Medicine for the Future 3 FDA Approved Products Therapeutic Areas of Focus: TNXP • CNS • ~$208 M cash as of • Infectious Disease December 31, 2025 • Immunology • No debt • Rare Disease • Expected cash runway into Q1’27 Partnerships with major Universities Fully I
Slide 4: TONMYA - the First FDA-Approved Treatment for Fibromyalgia in Over 15 Years
TONMYA - the First FDA-Approved Treatment for Fibromyalgia in Over 15 Years First-in-class, First-line Medicine Unique, Sublingual, Proprietary Formulation Supports: Efficacy, Absorption, and Tolerability Considerable Market Size Current Treatments TONMYA Opportunity High unmet need Limited approved
Slide 5: TONMYA Commercial Launch Underway
TONMYA Commercial Launch Underway • $1.4 million in net sales reported for the period November 17– December 31, 2025 (launch date was November 17th:~6 weeks, including holidays). • November 17, 2025, through February 27, 2026: • More than 1,500 prescribers have prescribed TONMYA to patients • Approx
Slide 6: The Need: Fibromyalgia is a Large, Underserved, and Dissatisfied Population
The Need: Fibromyalgia is a Large, Underserved, and Dissatisfied Population Chronic pain disorder, resulting from amplified sensory and pain signaling in the central nervous system Fibromyalgia symptoms: Patients and prescribers High patient churn on • Chronic widespread pain have expressed currentl
Slide 7: The Market for TONMYA
The Market for TONMYA >10 million U.S. 2.7 million patients Potential for growth adults are affected diagnosed and treated -Potential to increase diagnosis rates with renewed disease awareness and predominantly women1,2 annually3, majority are novel medication Debilitating and life-altering conditio
Slide 8: Patient and HCP Dissatisfaction has Led to Significant Off-label Use
Patient and HCP Dissatisfaction has Led to Significant Off-label Use Off-label Opioids are Commonly Prescribed within 18 Months of Fibromyalgia Diagnosis CBP, cyclobenzaprine; NSAID, nonsteroidal anti-inflammatory drug; SNRI, serotonin norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant
Slide 9: Targeted Commercial Approach: ~5% of Diagnosing HCPs Write ~70% of Prescriptions
Targeted Commercial Approach: ~5% of Diagnosing HCPs Write ~70% of Prescriptions1,2 We will move away from: Fibromyalgia-Diagnosing Traditional specialty-based decile targeting HCPs = 470K Hyper-focused To: one-on-one ~25K HCP targeting HCPs 5% of 470K = 25K HCPs 1,2 Paid Rx (APLD) in the recent 12
Slide 10: Best Practice Approach to Engage Top-prescribing HCPs
Best Practice Approach to Engage Top-prescribing HCPs Earned Media Omnichannel Surround Sound Corporate Communications Influencer Marketing Owned Social Channels Reputation Management KOL Engagement Search Engine Optimization Digital Media Paid Social Machine Learning Sales Force1 ~90 Reps Initially
Slide 11: TONMYA Together Provides Robust Patient Access & Support Services
TONMYA TogetherTM Provides Robust Patient Access & Support Services ACCESS PATHWAYS1 Payer Education & Traditional Pharmacy Digital Pharmacy Experience Engagement Savings Program Bridge Programs Live Payer Research Copay Support & Savings Program for Eligible and Value Analysis Streamlined Enrollmen
Slide 12: TONMYA - Uniquely Designed to Transform the Treatment Landscape
TONMYA - Uniquely Designed to Transform the Treatment Landscape © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 13: TONMYA's Formulation Delivers the Tertiary Amine Tricyclic by Transmucosal Absorption
TONMYA’s Formulation Delivers the Tertiary Amine Tricyclic by Transmucosal Absorption, Bypassing First-Pass Liver Metabolism The sublingual tablet rapidly disintegrates, dissolves, and TONMYA is administered Sublingual CBP enters the releases solubilized cyclobenzaprine (“CBP”) into the saliva subli
Slide 14: TNX-102 SL: Proprietary Eutectic Formulation
TNX-102 SL: Proprietary Eutectic Formulation Proprietary Cyclobenzaprine HCl Eutectic Mixture Stabilizes Sublingual Tablet Formulation Eutectic Cyclobenzaprine-HCl formulation1 (CBP-HCl) Mannitol (inactive) Base particle Base particle (K2HPO4) (K2HPO4) Base particle Cyclobenzaprine (K2HPO4) free bas
Slide 15: Approval Based on Studies that Demonstrated Significant Improvement in Pain Intensity Scores
Approval Based on Studies that Demonstrated Significant Improvement in Pain Intensity Scores in Fibromyalgia Patients Study 1 (RELIEF) Study 3 (RESILIENT) n=503 n=457 Pivotal Studies Included in Label Demonstrate Statistically Significant Mean Change from Baseline in Weekly Average of Daily 24-hour
Slide 16: Generally Well-Tolerated with an Established Safety Profile
Generally Well-Tolerated with an Established Safety Profile • In clinical studies: • The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were: oral hypoesthesia, oral discomfort, abnormal product taste, somnolenc
Slide 17: Clinical Pipeline
Clinical Pipeline © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 18: Key Clinical Programs
Key Clinical Programs MOLECULE* INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Phase 2 Field Study Planned 2027 Infectious TNX-4800 Seasonal Prevention and Human Challenge (CHIM) disease Human monoclonal Antibody of Lyme Disease Study Planned 2028+ Treatment of Acute Stress Phase 2 Topline Data Plan
Slide 19: TNX-4800 Monoclonal antibody prophylaxis against Lyme Disease
TNX-48001 Monoclonal Antibody Attacks Borrelia Monoclonal antibody prophylaxis • When a tick bites a TNX-4800 (mAb anti-OspA) treated animal, the mAb is ingested with blood and against Lyme Disease enters the tick midgut, binding to OspA protein on B. burgdorferi3,4 Long Acting anti-OspA monoclonal
Slide 20: TNX-102 SL For Acute Stress Reaction / Acute Stress Disorder
TNX-102 SL1 Large unmet need: For Acute Stress Reaction (ASR) / • ~60% of men and 50% of women in the US are exposed to at least one traumatic experience2 Acute Stress Disorder (ASD) • In the US, 1/3 of emergency dept. visits (40-50 million patients per year) are for trauma ASR/ASD are acute stress
Slide 21: TNX-102 SL For Major Depressive Disorder (MDD)
TNX-102 SL1 For Major Depressive Disorder Large market opportunity: (MDD) • Depression is an unmet need, despite multiple approved drugs2 • ~21 million U.S. adults experience at least TNX-102 SL is believed first-in-class for targeting one major depressive episode annually3 the disturbed sleep assoc
Slide 22: Tonix Priorities
Tonix Priorities Strategically Positioned for the Future Deliver Best-in-Class Advance Promising Drive Sustainable Growth to Launch Mid-Stage Pipeline Create Value for All Programs Stakeholders 22 © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 23: THANK YOU
THANK YOU PO6129 March 2026 1646 23 © 2026 Tonix Pharmaceuticals Holding Corp. © 2026 Tonix Pharmaceuticals Holding Corp.
Slide 24: TONMYA Important Safety Information (1 of 2)
TONMYA (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (1 of 2) IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TONMYA is contraindicated: In patients with hypersensitivity to cyclobenzaprine
Slide 25: TONMYA Important Safety Information (2 of 2)
TONMYA (cyclobenzaprine hydrochloride sublingual tablets) INDICATION: TONMYA is indicated for the treatment of fibromyalgia in adults. Important Safety Information (2 of 2) IMPORTANT SAFETY INFORMATION (CONT’D) ADVERSE REACTIONS The most common adverse reactions (incidence ≥2% and at a higher incide
Slide 26: ZEMBRACE Important Safety Information (1 of 2)
ZEMBRACE® Important Safety Information (1 of 2) ZEMBRACE SymTouch (ZEMBRACE) can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack: • Discomfort in the center of your chest tha
Slide 27: ZEMBRACE Important Safety Information (2 of 2)
ZEMBRACE® Important Safety Information (2 of 2) ZEMBRACE may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cra
Slide 28: TOSYMRA Important Safety Information (1 of 2)
TOSYMRA® Important Safety Information (1 of 2) TOSYMRA® can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop TOSYMRA and get emergency medical help if you have any signs of heart attack: • Discomfort in the center of your chest that lasts for
Slide 29: TOSYMRA Important Safety Information (2 of 2)
TOSYMRA® Important Safety Information (2 of 2) TOSYMRA may cause serious side effects including: • Changes in color or sensation in your fingers and toes; sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever; cramp
Tonix Pharmaceuticals Holding — BIO-Europe Spring 2026 on 6ix